2 Result: Pharvaris
Pharvaris Gains Momentum, Avalo Therapeutics and FibroGen Suffer Setbacks
June 26th, 2023
Shares of Pharvaris N.V. (Nasdaq: PHVS) surged over 10% in pre-market trading after the clinical-stage company announced that the U.S. Food and Drug Administration (FDA) has lifted the clinical hold on its Investigational New Drug (IND) application f. Read more
Pharvaris: Potential On-Demand HAE Treatment; Novartis Is To Takeover Chinook Therapeutics
June 12th, 2023
Pharvaris N.V. (Nasdaq: PHVS) released data from their Phase 2 study, RAPIDe-1, evaluating the on-demand treatment of hereditary angioedema (HAE) attacks with PHVS416 (deucrictibant immediate-release capsules). The study showed that treatment with. Read more
Want To Find Some News?
News By Industries
Recent Post
-
Wall Street Eyes Ciena, lululemon, and Broadcom Ahead of Earnings
December 07th, 2025Earnings Watch: What to Expect from Electrovaya, Nordson, and Synopsys
December 07th, 2025Earnings on Deck: AeroVironment, AutoZone, and Core & Main Set to Report
December 07th, 2025December 05th, 2025FDA Approves Nerve Scaffold for the Treatment of Sensory Nerve Discontinuity
December 04th, 2025
Member Login